Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks blood sugar swings in cancer patients with diabetes

NCT ID NCT07180251

Disease control Sponsor: National Taiwan University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at how daily ups and downs in blood sugar affect people who have both gastrointestinal cancer and diabetes after surgery. Researchers will track 260 participants to see if these changes impact self-care, blood sugar control, emotional distress, fatigue, and quality of life. In the second phase, some participants will try an 8-week education program using a continuous glucose monitor to help them better manage their health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CARE program (education with continuous glucose monitoring)
What this could lead to
If successful, this could lead to a better way to help people manage both diabetes and recovery after GI cancer surgery, improving their daily life and emotional well-being.
What could go wrong
This is an early-stage study with no control group for the main analysis, so results may not apply broadly. The intervention is behavioral, so benefits may vary by individual.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 260 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Individuals who are planning to undergo GI cancer surgery according to their physician's advice * Diagnosed with diabetes mellitus * Aged 18 or above * Can communicate in Mandarin or Taiwanese * Agree to participate and sign the informed consent form Exclusion Criteria: * People who are under active treatment for cancer other than GI cancer * Have a cognitive impairment * Do not know that they have GI cancer * Have medical-grade adhesives-related allergy (e.g., redness, swelling, heat, pain, itching, blisters or rash) * Diagnosed with thrombocytopenia or blood coagulation dysfunction

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes melletus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus digestive system cancer digestive system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes melletus Gastrointestinal cancers

Contacts and locations

Locations

  • National Taiwan University Hospital

    Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.